Questions
Ipamorelin questions, answered from the literature.
Direct answers, cited where there's a number behind them. No doses, no advice.
What does ipamorelin do for you?
In studies, ipamorelin triggers a selective pulse of growth hormone by activating the ghrelin receptor on the pituitary — without raising cortisol or prolactin, which is its defining feature [1]. In healthy volunteers that pulse peaks about 40 minutes after dosing and clears with a roughly 2-hour half-life [2]. What it does for a person beyond that is largely unproven: the one human efficacy trial missed its goal [3].
Does ipamorelin increase IGF-1?
Sometimes, depending on duration. Over short rodent dosing, ipamorelin raised bone growth with no measurable change in total IGF-1 [4]. But under sustained stimulation, the GH axis does lift IGF-1: a 30-day infusion of the class cousin GHRP-2 held IGF-1 and its binding proteins elevated in older adults without the response fading [8]. So a steady, longer GH drive is what tends to move IGF-1, not a single pulse.
What does ipamorelin peptide do?
Ipamorelin peptide is a five-amino-acid ghrelin mimetic that binds the GHS-R1a receptor on pituitary cells and releases a clean pulse of stored growth hormone [1]. The action is at the release step, not gene transcription [7], and it is selective — GH goes up, cortisol and prolactin do not [1]. It is wholly synthetic and not an approved medicine for any use [15].
Does ipamorelin build muscle?
No controlled human study has measured muscle growth from ipamorelin, so a muscle-building benefit is unproven. The mechanistic basis is the GH pulse it produces [1] and the GH axis's effect on tissue, plus animal data showing dose-dependent bone growth [4]. Community users report faster recovery, but that is anecdotal, not a measured increase in muscle mass.
What is ipamorelin?
Ipamorelin (NNC 26-0161) is the first selective growth hormone secretagogue — a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed by Novo Nordisk in the 1990s [1]. It releases GH by activating the ghrelin receptor while sparing cortisol and prolactin [1]. It was tested in one Phase 2 trial for postoperative ileus, which it failed [3], and has never been approved as a drug [15].
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid compound (a pentapeptide) that mimics the hunger hormone ghrelin at the GHS-R1a receptor to trigger a selective growth-hormone pulse [1]. Two D-form amino acids make it resistant to enzyme breakdown. In humans it has a terminal half-life of about 2 hours [2]. It is sold only as a research chemical and is not approved for human use [15].
What are the risks of ipamorelin?
The biggest documented risk is the unknown: there is no long-term human safety data, no Phase 3 trial, and no safety study of the subcutaneous route most people use [15]. The one short human trial showed no ipamorelin-specific safety signal over 7 days [3], but a related receptor agonist caused heart-muscle damage in rats over 28 days [6]. Mechanistic cautions also apply to glucose control and the GH/IGF-1–cancer axis.
Does ipamorelin reduce belly fat?
No human study has shown ipamorelin reduces belly fat. The closest measured data is a 2024 ferret study where ipamorelin cut chemotherapy-induced weight loss by about 24% — the opposite direction [5]. Community users occasionally report a gradually leaner look over weeks, but that is anecdotal and confounded by diet and training, not a demonstrated fat-loss effect.
What are the downsides of ipamorelin?
The central downside is that the evidence is thin and the only human efficacy trial failed its primary endpoint [3]. There is no approved use and no long-term safety record [15]. Commonly reported community nuisances — facial flushing, increased hunger, mild water retention, injection-site irritation — are anecdotal. A class-level cardiac signal exists from a related agonist in rats [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue — its clinical development simply stopped after its only Phase 2 trial (for postoperative ileus) missed its primary endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at an October 2024 advisory meeting, tightening compounding-pharmacy access [15].
What does CJC-1295 and ipamorelin do?
CJC-1295 and ipamorelin raise growth hormone through two different receptors — CJC-1295 as a GHRH analog, ipamorelin as a selective ghrelin-receptor GHRP [1]. The rationale for combining them is complementary-pathway synergy, shown for GHRP+GHRH pairings in related-peptide studies [9][10]. The combination itself has no published human outcome trial; its evidence is the pharmacology of its two parts.
How does CJC-1295 ipamorelin work?
CJC-1295 ipamorelin works by hitting two GH-raising pathways at once. CJC-1295 lifts the GHRH 'go' signal at the GHRH receptor; ipamorelin fires a selective GH pulse at the ghrelin receptor (GHS-R1a) [1]. Because the pathways are separate, the combination can exceed the additive GH response in class-level studies [9][10]. The combination has not been tested for any outcome in a published human trial.
How much CJC-1295 ipamorelin should I take?
No validated human dose exists, because no published trial has dosed the combination for any outcome. The single-agent human data is a pharmacokinetic study using IV infusions of 4.21–140.45 nmol/kg [2] and a Phase 2 trial using 0.03 mg/kg IV [3]; neither sets a self-administration dose. This site reports studied doses in third person and recommends none.
Does CJC-1295 ipamorelin work?
For raising growth hormone, the mechanism is sound and class-level studies show GHRP+GHRH synergy [9][10]; for the body-composition outcomes people actually seek, there is no controlled human trial of the combination, so efficacy for those goals is unproven. Single-agent ipamorelin's only human efficacy trial — for a different indication — also missed its endpoint [3].
How to reconstitute CJC-1295 ipamorelin 5mg?
This is a peptide-handling question, not a clinical procedure. Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically refrigerated. These are general handling notes from the research-supply literature, not a preparation instruction, and there is no validated human-use protocol.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours, with clearance of 0.078 L/h/kg [2]. The GH response it triggers is a single discrete pulse peaking around 40 minutes after dosing [2]. The peptide itself clears quickly; the downstream GH and IGF-1 effects can outlast the molecule.
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin receptor, and acute central administration of ghrelin and GH secretagogues activates the brain's appetite centers and induces feeding in rats [13]. Community users report increased hunger after dosing, described as milder than with older peptides like GHRP-6 but still present for some — anecdotal, not a measured human finding.
Will I gain weight on ipamorelin?
No human study answers this directly. By mechanism, the ghrelin-receptor route can increase appetite [13] and, in mice, ipamorelin stimulated fat gain even without GH [17] — so weight change is plausible but unproven in people. The one human trial (a short surgical study) was not designed to measure weight change [3]. Community reports vary and are anecdotal.
Does ipamorelin increase appetite?
Mechanistically yes — it is a ghrelin-receptor agonist, and ghrelin and GH secretagogues activate hypothalamic appetite centers and induce feeding in rats [13]. Community accounts describe a noticeable uptick in hunger in the hours after dosing, milder than with GHRP-6 but real for some users. No controlled human appetite study of ipamorelin exists; the human-relevant claim here is anecdotal plus class-level mechanism.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the GH pulse peaks about 40 minutes after a dose in human volunteers, and the peptide clears with a roughly 2-hour half-life [2]. Any felt effects people describe — like sleep changes — are reported anecdotally over the first one to two weeks, but those are community reports, not measured outcomes.
Does ipamorelin cause water retention?
No controlled human study has measured this for ipamorelin. By mechanism, GH excess is associated with sodium and water retention [1], and community users occasionally report mild, transient puffiness in the first few weeks, described as milder than with older GHRP compounds — anecdotal, not a clinical finding.
Where to inject CJC-1295 ipamorelin?
This site does not give injection instructions. For context only: the subcutaneous route is the one that dominates community use, and it is also the route with no published human safety or pharmacokinetic characterization [15]. The studied human routes were intravenous [2][3]. Nothing here is a how-to for self-administration.